Dr Wardak Abdul Qayoum assists the expat microbiologist in supervising the team and carrying out isolation, identification and sensitivity testing of the 3000 bacterial strains expected. He uses a plastic loop to take a colony of bacteria from the culture plate.

MSF has launched for the first time an Antibiotic Resistance Study in Lashkar Gah, Helmand, Afghanistan. A laboratory has been set up in the Boost Hospital where MSF works to carry out the study. The study started in January 2013.
Vivian Lee/MSF
Click to hide Text

WEBCAST: How MSF is Fighting Antibiotic Resistance

November 20 2019, 1:00pm - 2:30pm ET


For nearly fifty years, Doctors Without Borders/Médecins Sans Frontières (MSF) has been responding to the most urgent humanitarian crises around the world. But today we’re facing a different kind of emergency. In many of our projects, we see growing antimicrobial resistance—which means that many of the drugs we’ve relied on for decades to treat our patients are simply not working. Antimicrobial drugs, and antibiotics in particular, are invaluable tools to stop life-threatening infections, curb outbreaks, and save lives. So what will we do without them?

Join us for a panel discussion between MSF experts on our efforts to address the threat of antibacterial resistance (ABR), a mounting global health concern. From implementing new hospital and prescription protocols to pushing for research and development on new drugs to pioneering new diagnostic technologies, you’ll learn about how we’re fighting ABR in diverse contexts worldwide. Panelists will include Rupa Kanapathipillai, infectious disease specialist for MSF-USA, Richard Murphy, former MSF-USA infectious disease specialist and current professor at Harbor-UCLA Medical Center, and Nada Malou, MSF microbiology advisor. Betsy McKay, senior writer for the Wall Street Journal, will moderate the discussion.

At the time of the event, tune in to our webcast here. Audience Q&A will be provided via the chat.